Please assess the completion status of the following clinical trial:

Trial Title: The Role of Tapering Pace and Selected Traits on Hypnotic Discontinuation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. be currently using one or more BZD or newer BzRA hypnotics at bedtime for insomnia management;~2. have been using one or more such agents at least 5 nights per week for at least the past 12 months;~3. express interest in discontinuing hypnotic use and learning to manage their insomnia without medications;~4. report one or more failed attempts to discontinue hypnotic use in the past;~5. provide written consent to participate.~6. have an insomnia severity index score \> 10 indicating at least mild insomnia symptoms without sleep medication~Exclusion Criteria:~1. an untreated unstable, or in-treatment psychiatric disorder (e.g., major depression in psychotherapy or on a medication regimen that has been changed within the past 2 months)~2. a lifetime diagnosis of any psychotic or bipolar disorder~3. an imminent risk for suicide~4. evidence of alcohol or drug abuse (other than hypnotics) within the past year, since such abuse patterns suggest specialized substance abuse treatment may be indicated~5. unstable or terminal physical illness (e.g., cancer), neurological degenerative disease (e.g., dementia) or sleep disruptive medical condition (e.g. chronic pain)~6. current use of medications known to cause insomnia (e.g., corticosteroids)~7. a history or screening evidence of restless legs syndrome, circadian rhythm sleep disorder (e.g., delayed sleep phase syndrome), sleep apnea (AHI \> 5), or periodic limb movement disorder (PLM index \> 15)~8. habitual bedtimes later than 2:00 AM or rising times later than 10:00 AM; (i) consuming \> 2 alcoholic beverages per day at least 5 times per week~9. pregnant women or mothers with care-taking responsibilities for infants due to the sleep-disruption caused by such circumstances.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0% Hypnotic Medication Taper (Type: SHAM_COMPARATOR): In this condition patients will be maintained on their baseline hypnotic medication dosage throughout a 20-week double-blinded tapering period.
- 25% Hypnotic Medication Taper (Type: ACTIVE_COMPARATOR): In this condition patients will have their current hypnotic medication dosage reduced by 25% every 2 weeks throughout a 20-week double-blinded tapering period.
- 10% Hypnotic Medication Taper (Type: ACTIVE_COMPARATOR): In this condition patients will have their current hypnotic medication dosage reduced by 10% every 2 weeks throughout a 20-week double-blinded tapering period.

Based on this trial design, predict the completion outcome and termination type (if applicable).